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ABSTRACT The consumption of dietary fiber (DF) has increased since it was related to the prevention of a range of
illnesses and pathological conditions. DF can modify some gut hormones that regulate satiety and energy intake, thus also
affecting lipid metabolism and energy expenditure. Among these gut hormones are ghrelin, glucagon-like peptide 1, peptide
YY, and cholecystokinin. Adipose tissue is known to express and secrete a variety of products known as ‘‘adipocytokines,’’
which are also affected by DF. Some of the most relevant adipocytokines include adiponectin, leptin, tumor necrosis factor-a,
and interleukin-6. The release of adipocytokines, by either adipocytes or macrophage-infiltrated adipose tissue, leads to a
chronic subinflammatory state that could play a central role in the development of insulin resistance and type 2 diabetes,
therefore increasing the risk of cardiovascular disease associated with obesity. DF modulation of these molecules could also
have positive effects on obesity, insulin resistance, and hyperlipidemia. This review is focused on the effects of DF on the
above-mentioned gut peptides and adipocytokines.
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INTRODUCTION
It is well-established that nutrition can have a directimpact on normal physiological functions, as well as on
pathological conditions such as obesity, diabetes, and car-
diovascular disease. Dietary fiber (DF) is actually a group of
components in foods of vegetable origin (cereal, fruit, veg-
etables, and legumes) that are not broken down by human
digestive enzymes.1,2 DF is introduced at weaning and
consumed into adulthood, and elevated levels have been
demonstrated to be particularly protective against increased
body fat and glycemic dysregulation, even when a high-
energy diet is consumed.3 Nevertheless, the mechanisms
involved in the health-promoting effects of DF are unclear.
DF can be subdivided or classified into insoluble and sol-
uble DF. As its name suggests, insoluble DF is made up of
substances that do not dissolve in water (cellulose, hemicel-
lulose, lignin, and resistant starch). Its components resist the
action of intestinal microorganisms, and thus it can therefore
be classed as non-fermentable. Soluble DF is composed of
water-soluble elements with a gel-forming capacity (inulin,
pectins, gums, and fructo-oligosaccharides) that give volume
to feces. These substances predominate in legumes, cereals
(oats and barley), and some fruits and are used by intestinal
microorganisms, especially colonic flora. This type of DF is
therefore also known as fermentable DF.4 Reducing saturated
fat and cholesterol intake while increasing unsaturated fat
intake is a well-known healthy dietary objective, but the
importance of other dietary approaches, such as increasing
soluble DF intake, is nowadays increasingly recognized.5
Generally, the beneficial effects of DF could be due to its
actions in the digestive tract. Soluble DF delays glucose and
fat absorption, giving it an anti-obesity effect. It also influ-
ences postprandial glycemia and insulinemia and has
hypolipidemic effects.6 Furthermore, soluble DF fermenta-
tion by colonic microflora leads to the formation of short-
chain fatty acids (acetic, propionic, and butyric acids) that
are associated with the prevention of cardiovascular disease,
colorectal cancer, and inflammation.6 In addition, DF can
affect food intake by modulating the production of gut
hormones that are involved in appetite regulation. It spe-
cifically affects the orexigenic peptide ghrelin and some
anorexigenic hormones such as glucagon-like peptide-1
(GLP-1), peptide YY (PYY), and cholecystokinin (CCK).
These hormones would also affect lipid metabolism and
energy expenditure, thus influencing body weight.6,7
Adipose tissue has been traditionally considered an energy
storage depot with few interesting attributes. Because of the
dramatic rise in obesity and its metabolic sequelae over the
past decades, adipose tissue has garnered tremendous scien-
tific interest.8 In fact, adipose tissue is now known to be an
active metabolic tissue that secretes multiple metabolically
important proteins known as ‘‘adipocytokines.’’9 These adi-
pose tissue-derived factors play a central role in whole body
homeostasis by influencing a variety of biological and
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physiological variables and processes, including food intake,
energy balance, insulin action, lipid and glucose metabo-
lisms, angiogenesis and vascular remodeling, blood pressure,
and coagulation.10 DF modulation of adipocytokines could
also have positive effects on several pathologies, including
obesity, insulin resistance, and hyperlipidemia.
Bearing in mind the different experimental studies dem-
onstrating the benefits of DF on health, especially obesity,
the present review attempts to bring together the most im-
portant findings of the current research in this field, con-
centrating in particular on the effects of DF on the most
relevant gut peptides and the adipocytokines with key roles
in cardiometabolic diseases.
DIETARY FIBER AND GUT PEPTIDES
Ghrelin
Ghrelin, a 28-amino-acid peptide mainly produced in the
stomach mucosa, was identified in 1999 as the endogenous
ligand for the growth hormone secretagogue receptor.11
Subsequently circulating ghrelin levels were found to in-
crease under conditions that correlate with hunger in hu-
mans,12 and ghrelin administration induced eating in both
rats13 and humans.14 In addition to promoting growth hor-
mone secretion, ghrelin is the only known circulating orexi-
genic compound and, consequently, has received substantial
attention as an important factor in regulating mammalian
hunger and energy balance. Ghrelin is produced in many
different tissues, including the brain, pituitary, gonads, in-
testine, pancreas, lymphocytes, placenta, kidney, and lung.
However, more than 65% of circulating ghrelin is released by
the stomach mucosa. In addition to its hormonal function,
ghrelin is also thought to have local autocrine/paracrine ac-
tions helping to regulate processes such as cell proliferation,
adipogenesis, cardiovascular function, gastric secretion and
motility, glucose metabolism, and insulin production.15
It has been reported that fermentable fibers like fructans
are rapidly and extensively fermented in the proximal part of
the colon and may potentially modulate ghrelin levels.16
Very recently, it has been reported that the plasma ghrelin
levels were 23% lower after consumption of 3% b-glucan-
enriched bread compared with a control normal bread.17
Moreover, it has also been demonstrated that psyllium-
enriched meals decreased ghrelin response in healthy young
adults.18 Under fasting conditions, St-Pierre et al.19 also
observed positive associations between fiber intake and total
and acylated ghrelin levels. Their study suggested that fiber
intake is an important regulator of ghrelin levels both in
fasting and in hyperinsulinemic conditions in overweight
and obese postmenopausal women. Recently, other studies
reported that fermentable fiber inulin reduces ghrelin levels
in healthy subjects. According to Tarini and Wolever,20 the
mechanisms implicated in the fiber effects could be related
with the increase in content of short-chain fatty acids and the
reduction in levels of free fatty acids in the colon, something
that could attenuate type 2 diabetes. These researchers also
proposed that these fiber effects are in turn related with
ghrelin levels and regulate food intake.
GLP-1
GLP-1 is a gut-secreted peptide that has been proposed as
a potential antidiabetes/anti-obesity drug. This hormone is
also naturally secreted in response to meal ingestion, but it
is degraded rapidly after endogenous secretion or exogenous
injection.21 GLP-1 has been shown to mediate central ner-
vous system effects relating to satiety22 and cognition.23
The effect of DF on GLP-1 has been known for a long
time ago. In 1996, a diet supplemented with fiber was re-
ported to significantly modulate GLP-1. This novel finding
suggested a beneficial role for fiber in improving glucose
homeostasis.24
In 1998, it was reported that the ingestion of fermentable
fibers by healthy dogs for 14 days was associated with greater
GLP-1 secretion and smaller oscillations in postprandial
blood glucose concentrations.25 In the same year, another
research group demonstrated that cecal cell proliferation in-
duced by oligofructose leads to increase GLP-1 concentra-
tions in male Wistar rats fed a diet with or without 10%
oligofructose for 30 days.26 More recently, it has been re-
ported that oligofructose supplementation also improved
glucose homeostasis in diabetic rats previously treated with
streptozotocin. This phenomenon was partly linked to a re-
duction in food intake and was correlated with the increase in
colonic and portal GLP-1 content.27 Later, it was demon-
strated that the inclusion of high amylose-resistant cornstarch
in the diet may affect the energy balance through its effect as
a DF stimulator of GLP-1 expression, suggesting that this
increase in gut hormone signaling may be an effective natural
approach to the treatment of obesity.28 Zhou et al.21 provided
strong evidence that dietary resistant starch up-regulated total
GLP-1 in a sustained day-long manner in rodents. These in-
creases were associated with the fermentation of the fiber in
the lower intestine.21 Very recent studies have also revealed
that high DF levels increase plasma GLP-1 compared with
levels in animals consuming control and high-protein diets. In
addition, direct evidence exists that fermentation products
increased GLP-1 expression in vitro.21
PYY
PYY is a 36-residue gastrointestinal peptide primarily
synthesized in isolated mucosal endocrine cells scattered
through the colon and the ileum.29 Release of PYY is
stimulated by nutritive factors, in particular, the presence of
fat in the ileum and colon, and it is known that PYY inhibits
both pancreatic and gastric secretion.30 PYY has been pro-
posed as a potential antidiabetes/obesity hormone, and re-
cent studies have demonstrated a relation between DF intake
and these pathologies.
When a 14-week treatment of Viscofiber (Cevena Bio-
products Inc., Edmonton, AB, Canada) obtained from oats
and barley (4 g/day) was combined with a lifestyle change
program, weight loss and an increase in fasting PYY levels
were observed.31 In addition, the short-term consumption of
b-glucans from barley was able to control appetite by mod-
ulating sensations and reducing energy intake, and the re-
searchers suggested that the satiety effect of b-glucans may
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be mediated by an increase of PYY.17 In this context, Beck
et al.32 also demonstrated that an increase in the dose of
b-glucan produced significantly higher levels of plasma PYY
at 2–4 hours after consumption. Short-chain fatty acids di-
rectly increased PYY promoter activity in an in vitro study.28
It was reported that PYY mRNA expression was higher in the
cecum and colon of resistant starch-treated rats. It is inter-
esting that dietary resistant starch did not affect PYY gene
expression in the ileum, although the highest non-induced
expressions for these genes were detected in the ileum. Thus,
the stimulating factor that specifically responds to dietary
resistant starch might only exist in the lower intestine, where
resistant starch ferments to produce short-chain fatty acids.21
CCK
CCK is one of the first gastrointestinal hormones to be
discovered, and it is one of the most abundant neuropeptides
in the brain. It was originally isolated from porcine duode-
num as a 33-amino-acid peptide.33,34 Major biological ac-
tions of CCK are the reduction of food intake and the
induction of anxiety-related behavior.35
It has been demonstrated that there is a link between the
intake of DF and the increase of CCK. In 1992, nine healthy
male volunteers received three different isocaloric diets via
intraduodenal perfusion; the highest CCK plasma values
were observed in those fed a high-molecular diet enriched
with fat and fiber.36 Other researchers evaluated the effects
of a completely soluble fiber on fasting and postprandial
CCK hormone levels in 25 obese but otherwise healthy fe-
males; the results indicated that a hydrolyzed guar gum fiber
supplement produced a heightened postprandial CCK re-
sponse.37 Moreover, when 11 healthy men were fed barley-
containing meals, CCK remained elevated for a longer time
after the intake.38 Nevertheless, this same research group
later performed another study in which men consumed
beans as a source of DF and a control meal in random order,
and the CCK response was twice as high after the bean-
containing meal than after the control meal.39 Recently, it
has been observed that b-glucan improved satiety, and the
release of CCK is probably part of the mechanism impli-
cated in this effect.40 Burton-Freeman et al.41 in 2002 sug-
gested that the properties of fibers that prolong the exposure
of meal contents, in particular dietary fat, to the intestinal
mucosa could contribute to the increase in subjective satiety
during the postmeal period, and it has been postulated that
these effects of DF on satiety may be mediated, at least in
part, through prolonged release of CCK.
Effects on the four gut peptides discussed here are sum-
marized in Table 1.
DIETARY FIBER AND ADIPOCYTOKINES
Adiponectin
Adiponectin is an abundant multifunctional adipocyte-
derived protein with anti-inflammatory, anti-atherogenic, and
insulin-sensitizing activity.42 Adiponectin has sequence
homology to the C1q family of complement proteins and
circulates in low-, medium-, and high-molecular-weight
forms. Clinical data indicate that the high-molecular-weight
form strongly correlates with improved insulin sensitivity and
glucose tolerance, whereas the association of total adipo-
nectin levels with these factors is not as strong.43 Adiponectin
levels have been shown to be lower in males, obesity, insulin
resistance, patients with type 2 diabetes mellitus, coronary
artery disease, and essential hypertension.44–48 In addition, it
is known that there is a link between the diet and the levels
of this adipocytokine because it has been demonstrated
that adiponectin concentrations decrease transiently after
consumption of a high-carbohydrate, low-fiber meal.49
Several studies have demonstrated that adiponectin levels
are increased with DF intake. Galisteo et al.50 observed that
prolonged feeding with a 3.5% Plantago ovata husk-
supplemented diet prevents endothelial dysfunction and the
development of hypertension in obese Zucker rats, effects
that are accompanied by a decrease in body weight gain,
reduced hyperinsulinemia and dyslipidemia, and restora-
tion of plasma adiponectin concentration. A cross-sectional
analysis in women with type 2 diabetes revealed that the
intake of cereal fiber and fruit fiber was significantly asso-
ciated with increasing plasma adiponectin concentrations.
These data indicate that dietary cereal fiber as well as the
glycemic load and the glycemic index are associated with
circulating adiponectin concentrations in humans.51 How-
ever, these associations were not modified by obesity sta-
tus.52 Recently, Yannakoulia et al.53 indicated that a dietary
pattern characterized by high consumption of whole-grain
cereals was significantly, yet modestly, positively related to
circulating adiponectin concentrations; they observed that a
potential beneficial effect on adiponectin levels could in-
duce health benefits not only on the insulin and glucose
metabolism, but also on changes in inflammatory markers or
other adipocytokines. In this sense, in cultured cells, adi-
ponectin has been shown to reverse the deleterious effects of
tumor necrosis factor-a (TNF-a) and other cytokines on
endothelial function. TNF-a-induced expression of several
adhesion molecules, including vascular cell adhesion
molecule-1, E-selectin, and intercellular adhesion molecule-
1, was blocked by adiponectin.54,55 Nilsson et al.56 reported
that an evening meal consisting of kernel-based barley bread
Table 1. Effects of Dietary Fiber on Gut Peptides
Effect Fiber Reference
[Ghrelin Fructans Wang et al.16
Psyllium Karhunen et al.18
b-Glucan Vitaglione et al.17
[Glucagon-like
factor-1
Fermentable plant fibers Massimino et al.25
Resistant starch Zhou et al.21
Inulin/oligofructose DeVries et al.1
[Peptide YY b-Glucan Vitaglione et al.17
Beck et al.32
[Cholecystokinin Oat and barley Viscofiber Greenway et al.31
Dry beans Bourdon et al.38
b-Glucan Beck et al.32
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resulted in higher concentrations of adiponectin the fol-
lowing morning compared with a wheat flour bread, indi-
cating anti-inflammatory properties from the ordinary barley
kernel bread product. Our research group has evaluated the
adiponectin plasma levels in several groups of obese Zucker
rats fed different fibers. The rats fed an apple pectin fiber,
and particularly those fed a soluble cocoa fiber product,
showed higher adiponectin plasma levels than the rats fed a
standard diet.57 Adiponectin plasma levels are therefore
conditioned by DF ingestion and are important for health. In
fact, adiponectin inhibits atherosclerosis, suggesting that
this protein might prevent the onset and progression of
cardiovascular diseases. It has been suggested that high-
molecular-weight adiponectin is a useful marker for the
evaluation and care of subjects with metabolic syndrome
and related disorders.58
Leptin
Leptin is the protein product encoded by the obese (ob)
gene. It is a circulating hormone primarily produced by adi-
pose tissue.59 Since its identification in 1994, leptin has at-
tracted much attention as one of the most important signals
for the regulation of food intake and energy homeostasis.60–62
Leptin binds to its receptors in various regions of the central
nervous system, including the hypothalamus and brainstem,
where it activates neural pathways that decrease appetite and
increase sympathetic nervous system activity and energy
expenditure.63,64 Although changes in food intake and total
body fat can clearly affect insulin sensitivity in peripheral
tissues, several observations suggest that leptin regulation of
glucose homeostasis occurs independently of its effects on
food intake through central and peripheral mechanisms.8
It is known that obesity in humans is associated with hy-
perleptinemia, and increased adiposity is believed to be as-
sociated with development of leptin resistance.16 Some
researchers have observed that in conditions of high-sugar/
low-fiber, glucose and leptin levels decreased more slowly
(glucose levels were still high at 60 minutes, and leptin levels
at 90 minutes) than in a low-sugar/high-fiber condition.65
Other researchers showed that circulating leptin was de-
creased after supplementation with DF-rich fungal chitosan
and that this effect was related to lower fat mass development
(adiposity index).66 However, no effects of white bread rolls
supplemented with 15 g of arabinoxylan for 6 weeks were
observed on leptin levels in type 2 diabetic subjects.67
Pro-inflammatory cytokines
TNF-a. TNF-a, an inflammatory cytokine produced by
macrophages/monocytes during acute inflammation, is re-
sponsible for the diverse range of signaling events within
cells that lead to necrosis or apoptosis.68 This cytokine is not
secreted by adipocytes, but it is secreted by macrophages
infiltrating adipose tissue, and it functions as a paracrine
and/or autocrine factor.69,70 TNF-a is suspected to play a
role in obesity and concomitant metabolic disturbances,
such as insulin resistance, and is one of the most important
mediators of inflammation.71,72
The modulation of TNF-a levels after consumption of DF
has been studied. Some researchers evaluated whether long-
term intake of a fiber-supplemented diet (3.5% P. ovata
husks) had preventive effects on the development of ab-
normalities in the experimental model of obese Zucker rats.
Their results revealed reduced circulating concentrations of
TNF-a in the animals treated with this fiber.50 Another study
affirmed that partially hydrolyzed guar gum inhibited in-
creases in intestinal TNF-a protein and mRNA expression
after dextran sulfate sodium administration in mice.73 In
addition, very recently, in 2010, Galisteo et al.74 also ob-
served that the increased TNF-a levels found in obese
Zucker rats were significantly improved when these rats
were fed a P. ovata husk-supplemented diet. Very recently,
our research group has evaluated the TNF-a plasma levels in
obese Zucker rats fed different fibers and has observed a
decrease in this protein when the rats were fed b-glucan,
apple pectin, or soluble cocoa fiber.57 Many studies have
suggested that a high-fiber diet might be a tool to reduce
inflammation, and therefore a way to reduce diseases that
are associated with increased inflammation. This is quite
important because the identification of dietary factors that
reduce inflammation could have undoubted significant
public health implications for the prevention of diabetes
mellitus, cardiovascular disease, and metabolic syndrome.75
There are several mechanisms to explain the possible
positive effect of DF on inflammation. It is known that while
a high-fat, high-carbohydrate meal induces oxidative stress
and inflammation, including priming the transcription of
genes for pro-inflammatory compounds like TNF-a, a meal
rich in fiber and fruit does not. In addition, a high-fat, high-
carbohydrate meal induces a concomitant increase in the
plasma concentration of endotoxin and the expression of its
specific receptor, Toll-like receptor-4. This combination
provides a further pro-inflammatory mechanism that is rel-
evant to subsequent meals because both of these effects last
for more than 5 hours. In contrast, a meal rich in fiber and
fruit does not induce these effects.76
Interleukin-6 and interleukin-8. Interleukin-6 (IL)-6 is a
pro-inflammatory cytokine produced by several cells (fibro-
blasts, endothelial cells, monocytes) and adipose tissue, and
its content is increased in obesity.77,78 Approximately 30% of
circulating IL-6 is derived from white adipose tissue, with
visceral fat producing higher levels of IL-6 than subcutaneous
fat.79 In addition, plasma IL-6 is highly correlated with body
mass and inversely related to insulin sensitivity.80,81 IL-8 can
also be synthesized in adipose tissue,82 and this pro-inflam-
matory cytokine is also implicated in the development of
insulin resistance. In particular, in obese subjects, IL-8 con-
centrations are correlated inversely with insulin sensitivity.83
The intake of carbohydrate and fiber modulates inflam-
mation. In fact, a prolonged postprandial inflammatory re-
sponse after high-fat, high-carbohydrate meals has been
described in obese individuals.84 In contrast, DF has been
related to a decrease in pro-inflammatory cytokine levels
and may acutely reduce inflammatory activity.49 Nilsson
et al.56 demonstrated in 2008 the anti-inflammatory
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properties of a kernel-based barley bread administered in the
evening meal. The intake of this bread resulted in lower
concentrations of IL-6 the following morning compared
with a wheat flour bread in the evening meal. Another study,
carried out by Manning et al.85 in 2008, indicated that
plasma IL-6 concentrations increased to levels substantially
above baseline in the late postprandial period after meals
rich in high glycemic index carbohydrates with and without
fat and after ingestion of low glycemic index, high DF
carbohydrates. This response of plasma IL-6 to the meals
was markedly higher in obese women than in lean women
and was lower after ingestion of low glycemic index, high
DF carbohydrates than that of high glycemic index, low DF
carbohydrates. Therefore, according to these researchers,
obesity enhances the postprandial increase in IL-6 in women
irrespective of the type or content of fat in the meal, and DF
attenuates this increase insofar as IL-6 is concerned.85 In
another study, total DF intake was also significantly and
inversely associated with different inflammation markers,
such as IL-6, in nondiabetic men (60–79 years old) followed
for 7 years.86 It has been also demonstrated that after con-
sumption of a diet supplemented with 5% fungal chitosan
for 10 weeks the IL-6 levels decreased in the serum of obese
mice.66 In addition, Sofi et al.87 have also indicated in 2010
that the short-term dietary intake of a whole grain bread
obtained from an old grain variety lowers circulating levels
of atherosclerosis markers such as IL-8. Moreover, butyrate,
one of the major metabolites of dietary fiber, dose-dependently
inhibited TNF-a and IL-8 secretion in the human intestinal
epithelial cell line HT-29.88
In the context of all these ideas, it is important to keep in
mind that inflammation may be a mechanism through which
high postprandial insulin and glucose responses increase the
risk of type 2 diabetes mellitus.89 An increased intake of
total DF was inversely associated with markers of insulin
resistance,90 and consumption of soluble DF reduces the
postprandial glucose response after carbohydrate-rich
meals.91 Colonic fermentation with the production of short-
chain fatty acids can be observed with most types of DF to
some extent, but it tends to be more pronounced with soluble
DF in naturally available foods.92 Commonly, increased
production of short-chain fatty acids is assumed to be benefi-
cial in that it reduces hepatic glucose output and improves lipid
homeostasis.93 Nevertheless, it is not soluble DF, but rather the
consumption of insoluble cereal DF and whole grains, that has
been consistently associated with a reduced risk of type 2 di-
abetes in large prospective cohort studies.94,95
After a high-carbohydrate meal, DF could therefore reduce
the increased postprandial levels of pro-inflammatory cyto-
kines that are inversely correlated with insulin sensitivity.
The mechanisms responsible for the anti-inflammatory and
antidiabetic effects of dietary fiber have not yet been com-
pletely elucidated, but, in any case, our meals and eating
patterns in today’s modern society are partial to high-fat,
high-carbohydrate pro-inflammatory meals, which are low in
fiber, and the effects of diets rich in fiber appear beneficial
from the view point of the prevention of diabetes as well as
inflammation.76
Effects on the four adipocytokines discussed here are
summarized in Table 2.
CONCLUSIONS
In this review, we have described the beneficial effects of
DF on different gut peptides and adipocytokines. In fact, all
of the above-mentioned information allows us to conclude
that the bioactive effects of DF are, at least in part, mediated
by the modification of gut peptides and adipocytokines. The
inclusion of easily consumed fiber as part of our daily diet,
in appropriate quantities, could be a very attractive strategy
to improve health. DF could be used as a functional food
ingredient. However, further studies focused on elucidating
the molecular mechanisms and the intracellular signaling
pathways involved in the different DF effects are needed.
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